Increasing the duration and efficacy of intravenous chemotherapy using a patient-centered digital education program: Navigating Cancer’s program for patients receiving pemetrexed for lung cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e18025-e18025
Author(s):  
Scott C. Howard ◽  
Timothy Joseph Yeatman ◽  
Mark Layton Watson ◽  
Catherine Lam
Keyword(s):  
Lung Cancer ◽  
Patient Education ◽  
Cancer Patients ◽  
Education Program ◽  
Smoking Status ◽  
Multivariable Analysis ◽  
Patient Portal ◽  
Educational Materials ◽  
Specific Patient ◽  
Lung Cancer Patients

e18025 Background: Adherence to therapy improves survival in cancer patients. Patient education interventions have effectively improved adherence to oral drugs, but have not been studied for intravenous drugs. Methods: We assessed impact of a pemetrexed educational program for lung cancer patients from 58 oncology practices delivered from 2014-2016 via the Navigating Cancer (www.navigatingcancer.com) patient portal. After online registration, the program provided sequential messages about pemetrexed therapy and management of side effects. Access to each component of the education program was tracked and de-identified data provided to the study team for analysis. Results: Of 944 patients, 441 (47%) accessed pemetrexed-specific educational materials, and were more likely to be Caucasian (p=0.01) and to have never smoked (p=0.05). Patients who accessed educational materials received a mean of 286 days of pemetrexed versus 236 days (p<0.01); their one-year survival was 66% (SE 2.8%) versus 53% (SE 2.9%) (p<0.01). In multivariable analysis, survival was predicted by accessing education (p<0.01), but not race or smoking status (p>0.1). Conclusions: Drug-specific patient education delivered via a patient portal and email reached 47% of registered patients and was associated increased duration of therapy and improved survival. [Table: see text]

Selecting a PRO-CTCAE based subset for patient reported symptom monitoring during lung cancer treatment (Preprint)

2020 ◽  
Author(s):  
Evalien Veldhuijzen ◽  
Iris Walraven ◽  
Jose Belderbos
Keyword(s):  
Lung Cancer ◽  
Clinical Practice ◽  
Cancer Patients ◽  
Treatment Modalities ◽  
European Organization ◽  
Specific Patient ◽  
Symptom Monitoring ◽  
Lung Cancer Patients ◽  
Wide Range ◽  
Patient Reported

BACKGROUND The Patient Reported Outcomes Version of the Common Terminology Criteria of Adverse Events (PRO-CTCAE) item library covers a wide range of symptoms relevant for oncology care. To enable implementation of PRO-CTCAE-based symptom monitoring in clinical practice, there is a need to select a subset of items relevant for specific patient populations. OBJECTIVE The aim of this study was to develop a PRO-CTCAE subset relevant for patients with lung cancer. METHODS The PRO-CTCAE-based subset for lung cancer patients was generated using a mixed methods approach based on the European Organization for Research and Treatment of Cancer (EORTC) guidelines for developing questionnaires, consisting of a literature review and semi-structured interviews with both lung cancer patients and health care practitioners (HCPs). Both patients and HCPs were queried on the relevance and impact of all PRO-CTCAE items. Results were summarized and, after a final round of expert review, a selection of clinically relevant items for lung cancer patients was made. RESULTS A heterogeneous group of lung cancer patients (n=25) from different treatment modalities and HCPs (n=22) participated in the study. A final list of eight relevant PRO-CTCAE items was created: decreased appetite, cough, shortness of breath, fatigue, constipation, nausea, sadness, and pain (general). CONCLUSIONS Based on literature and both professional and patient input, a subset of PRO-CTCAE items has been identified for use in lung cancer patients in clinical practice. Future work is needed to confirm the validity and effectiveness of this PRO-CTCAE lung cancer subset internationally, and in the real-world clinical practice setting.

Development and Evaluation of Patient Education Materials for Elderly Lung Cancer Patients

2015 ◽  
Vol 31 (1) ◽  
pp. 70-74 ◽  
Author(s):  
Natalie Jewitt ◽  
Andrew J. Hope ◽  
Robin Milne ◽  
Lisa W. Le ◽  
Janet Papadakos ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Patient Education ◽  
Cancer Patients ◽  
Lung Cancer Patients

scholarly journals Braf and erbB2 mutations correlate with smoking status in lung cancer patients

2012 ◽  
Vol 3 (5) ◽  
pp. 771-775 ◽  
Author(s):  
HIDEFUMI SASAKI ◽  
MASAYUKI SHITARA ◽  
KEISUKE YOKOTA ◽  
KATSUHIRO OKUDA ◽  
YU HIKOSAKA ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Smoking Status ◽  
Lung Cancer Patients

Clinical significance of cytokines levels in exhaled breath condensate (EBC) and serum of lung cancer patients.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e22202-e22202
Author(s):  
Georgia Lamprodimou ◽  
Athanasios Athanasiadis ◽  
Theodora Kerenidi ◽  
Dimitrios Doufexis ◽  
Martha Lada ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Smoking Status ◽  
Prognostic Significance ◽  
Stage Iv ◽  
Serum Levels ◽  
Rank Test ◽  
Exhaled Breath ◽  
Lower Serum ◽  
Lung Cancer Patients

e22202 Background: Cytokines are known to play an important role in carcinogenesis.The aim of this study is to measure pre-treatment concentrations of cytokines IL6, IL10, IL1β and IL8, in EBC and serum of lung cancer patients and to assess any possible association with clinicopathological variables and survival. Methods: From February 2010 to May 2011 we enrolled 73 patients with previously untreated lung cancer, 67 males and 6 females, age 67.7±9.5 years, 46 smokers and 27 ex-smokers, and 30 healthy individuals as controls. Sixty-one patients had NSCLC and 12 SCLC (5 stage I, 3 stage II, 19 stage III and 46 stage IV). EBC was collected using the Ecoscreen device (Viasys, Germany). Serum and EBC levels of cytokines were analyzed by commercially available enzyme-immunosorbent assay kits (ELISA). Results: All cytokines but IL8 were detectable in both materials. IL8 was not detected in EBC. All cytokines were significantly increased in patients with lung cancer in comparison to controls (IL6: serum P<0.0001, EBC P=0.001; IL10: serum P= 0.006, EBC P=0.037; IL1β: serum P= 0.032, EBC P=0.005; IL8 serum P=0.001). Moreover, a statistically significant correlation was found between IL10 levels in EBC and serum (P=0.001, Rho=0.334). In EBC, higher levels of IL6 were found in patients with T3-T4 disease than in those with T1-T2 [4.27 pg/ml (2.46-5.99) vs 3.12 pg/ml (1.35-5.03), P=0.036]. Furthermore, smokers had higher serum levels of IL6 compared to ex-smokers [10.19 pg/ml (4.92-17.38) vs 4.46 pg/ml (1.88-11.53), P=0.009]. Finally, lower serum levels of IL6 < median value (9.55pg/ml) were associated with improved survival (median overall survival 338 days vs 237 days Log Rank test, P= 0.046). Conclusions: Elevated levels of measured cytokines were found in both EBC and serum of lung cancer patients. Particularly, IL6 levels were related to T-stage and smoking status, while lower serum levels of IL6 with survival. These findings suggest that cytokines should be further studied in order to evaluate their diagnostic and prognostic significance. EBC could provide a simple, noninvasive and economic method for the monitoring of biomarkers in patients with lung cancer.

Reduction of emergency department utilization via access to outpatient cancer care.

2014 ◽  
Vol 32 (30_suppl) ◽  
pp. 128-128 ◽  
Author(s):  
Kenneth D. Bishop ◽  
Mary Anne Fenton ◽  
Tara Szymanski ◽  
Megan Begnoche
Keyword(s):  
Lung Cancer ◽  
Emergency Department ◽  
Patient Education ◽  
Cancer Patients ◽  
Emergency Department Utilization ◽  
Primary Tumor Site ◽  
Lung Cancer Patients ◽  
Oncology Nurse ◽  
Ed Visits ◽  
Education Process

128 Background: Emergency department (ED) utilization for non-emergent medical problems is an inefficient use of medical resources. During calendar year 2013, 224 RIH adult cancer patients presented to the RIH ED. Retrospective review indicated up to 50% of these ED visits were avoidable. Methods: This project was developed for the ASCO Quality Training Program. A multidisciplinary team was assembled to address ED utilization. Retrospective chart review of ED visits included time and reason for visit and primary tumor site. The team selected the Lung Cancer as the target group, developed a cause-and-effect analysis for ED visits, administered a patient survey, and implemented a series of Plan-Do-Study-Act (PDSA) cycles. The team implemented a patient education process of nurse sick-line symptom management and same-day sick visits at RIH CCC as well as developing a single-page patient “sick-line tool” with oncology nurse sick-line contact telephone numbers. A patient navigator introduced the sick-line tool at the first visit and its usage was reinforced at subsequent visits. Results: For RIH CCC lung cancer patients, a standardized symptom-control education process correlated with 30% decrease in ED visits for any presenting complaint (42 visits vs. 60 visits) and 32% decrease in ED visits with presenting complaint of pain (13 visits vs. 19 visits) during January/February 2014 compared to January/February 2013. We did not find significant differences between the proportion of ED visits during Cancer Center business hours, evenings, or weekends. Sick-line calls were found to increase by 53% during January 2014 compared to December 2013 with an additional 35% increase in February 2014. Conclusions: A standardized patient education process resulted in a significant decrease in ED visits, concurrent with an increase in outpatient sick-line utilization. This may reflect an improvement in efficiency of outpatient cancer patient care in a single-institution setting. Given other reports of increased ED utilization by lung cancer patients for similar presenting reasons, these improvements may be generalizable to other institutions.

scholarly journals Smoking status at diagnosis and histology type as determinants of long-term outcomes of lung cancer patients

2012 ◽  
Vol 43 (5) ◽  
pp. 919-924 ◽  
Author(s):  
Michael Poullis ◽  
James McShane ◽  
Mathew Shaw ◽  
Michael Shackcloth ◽  
Richard Page ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Smoking Status ◽  
Long Term Outcomes ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document